Aptabio Therapeutics

Reactive-oxygen-species-targeted therapeutics

293780 · KOSDAQ · South Korea

Public Market Listing

293780KOSDAQ

KOSDAQ primary exchange listing

Live quotes, historical charts, and market capitalization for Aptabio Therapeutics are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Pan-NOX (NOX1/2/4)Small molecule
Type 2 DiabetesChronic Kidney Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
IsuzinaxibPhase 2Diabetic Kidney Disease (DKD)
Est. primary completion 2027-06-30 · NCT06962098 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.6M——$12Mreport ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$2.5M——$22Mreport ↗
2023-FY$0.3M——$9.3Mreport ↗